ABSTRACT
The present study reports the synthesis of silver nanoparticle using Morus nigra leaf extract were used as reducing agent for reduction of silver nitrate solution. The synthesis of silver nanoparticles was analyzed by UV-Visible spectroscopy, Scanning Electron Microscopy. The SEM analysis has shown that size of silver nanoparticles synthesized from leaves extract of M.nigra was 200 nm and seems to be spherical in morphology. Morphology of chemically synthesized silver nanoparticles is nearly spherical and of size ranges from 300-500 nm. The average particle size analyzed from SEM analysis was observed to be 350 nm. This article has discussed the synthesis of silver nanoparticles generated from plant extract, characterization and antibacterial analysis. In this study the antibacterial activity was examined against six MTCC cultures collected from IMTECH Chandigarh, Including both gram positive and gram negative bacteria such as P.aeruginosa, S.aureus, B.subtilis, E.coli, P.flourescens and Streptococus mutans. Out of these strains the antimicrobial activity of the silver nanoparticles showed maximum zone of inbhition against P.flourescens (22 mm), P.aeruginosa (19 mm), S.aureus (18 mm) and least effective against E.coli (15mm). In contrast chemically synthesized silver nanoparticles were found most effective against S.aureus (13 mm) and B.subtilis (12mm) and almost ineffective against Streptococcus mutans (6 mm) and P.flourescens (4 mm). In the concluding remarks, the silver nanoparticles synthesized using M.nigra leaves extract would be a better antimicrobial effective against various bacterial species.
ABSTRACT
BACKGROUND: Hepatitis A virus (HAV) vaccination is recommended worldwide for patients with chronic liver disease to prevent decompensation due to superinfection with HAV. India being endemic for HAV, the prevalence of pre-existing antibodies against HAV due to subclinical exposure to the virus in childhood among patients with chronic liver disease may be high and, therefore, vaccination may not be needed. However, data are lacking on the prevalence of HAV antibody among patients with chronic liver disease in India. METHODS: Two hundred fifty-four patients attending the Liver Clinic at the All India Institute of Medical Sciences, New Delhi during the past 5 years and diagnosed to have either chronic hepatitis due to the hepatitis B virus (n = 76), hepatitis C virus (n = 84) or cirrhosis of the liver due to the hepatitis B (n = 47) or C (n = 47) virus were tested for the presence of IgG anti-HAV antibody in their sera (using a commercial ELISA kit). RESULTS: Two hundred forty-eight (97.6%) patients tested positive for IgG anti-HAV. The prevalence of anti-HAV positivity was similar among patients with chronic hepatitis B (74, 97.4%), chronic hepatitis C (82, 97.6%), cirrhosis of the liver due to the hepatitis B (46, 97.8%) and hepatitis C (46, 97.8%) virus. CONCLUSION: Vaccination against HAV is not required among patients with chronic liver disease in India as there is a very high prevalence of pre-existing antibodies in these patients.